The wealth management businesses of Chinese investment banks in Hong Kong are growing faster than those of international rivals, as a buoyant initial public offering (IPO) market and rising cross-border flows strengthen their competitive edge. “Chinese investment banks are seeing accelerated growth … because [their] base is smaller and the current market environment favours them,” said Wang Lei, C...
The wealth management businesses of Chinese investment banks in Hong Kong are growing faster than those of international rivals, as a buoyant initial public offering (IPO) market and rising cross-border flows strengthen their competitive edge. “Chinese investment banks are seeing accelerated growth … because [their] base is smaller and the current market environment favours them,” said Wang Lei, CEO of Huatai Financial Holdings (Hong Kong) , in an interview with the South China Morning Post, adding that foreign rivals were also expanding, but at a slower pace. “Hong Kong is a key centre for Chinese residents’ global asset allocation,” said Wang, who chairs the private wealth management committee at Huatai Securities. “Its wealth management market is increasingly entering a state of intensified competition.” Advertisement Regulators’ data is backing up this assessment. A survey published in July by the Securities and Futures Commission (SFC) showed that assets under management of mainland-related firms in Hong Kong grew 15 per cent to HK$3.09 trillion (US$448 billion) in 2024, outperforming the industry average for a fifth consecutive year. Their net fund inflows jumped 68 per cent to HK$256 billion in 2024, while headcount rose 5 per cent year on year, the survey said. Advertisement Meanwhile, some foreign private banks have been retreating from Hong Kong. Banque Internationale a Luxembourg, the Grand Duchy’s oldest bank, shut its Hong Kong wealth management office in early 2025, while Liechtenstein’s VP Bank closed its Hong Kong office in 2024 after 18 years.
AI is having a clear effect on how companies think about dividends in corporate America. In 2026 alone, companies tied to artificial intelligence infrastructure have been raising their payouts at a pace that would have looked unusually strong just a few years ago. GE Aerospace (GE) raised its quarterly dividend by 31%, Monolithic Power Systems (MPWR) increased its payout by 28%, and Equinix (EQIX)...
AI is having a clear effect on how companies think about dividends in corporate America. In 2026 alone, companies tied to artificial intelligence infrastructure have been raising their payouts at a pace that would have looked unusually strong just a few years ago. GE Aerospace (GE) raised its quarterly dividend by 31%, Monolithic Power Systems (MPWR) increased its payout by 28%, and Equinix (EQIX) lifted its dividend by 10%, while also committing to grow it by at least 8% a year for the next five years. These are not small increases. They show that companies benefiting from AI demand are bringing more of that cash back to shareholders. Applied Materials (AMAT) just sent a similar message. On March 13, 2026, the company's board of directors approved a 15% increase to its quarterly cash dividend, raising it from $0.46 to $0.53 per share, payable June 11, 2026. That move marks nine straight years of dividend growth. CFO Brice Hill said the company has more than doubled its dividend per share over the past four years, with the payout growing at an 18% annual rate over the last decade. Over the past 10 fiscal years, Applied has also returned nearly 90% of its free cash flow to shareholders through dividends and share buybacks combined. That kind of record from a chip equipment company deeply tied to the AI chip market raises a fair question: with AMAT's dividend growing faster than most and its business becoming more important to the future of chip manufacturing, is this a stock worth owning right now? Let’s find out. The Numbers Behind the Bull Case for AMAT Applied Materials makes the tools chip companies use to produce advanced semiconductors, and it makes most of its money by selling wafer fabrication equipment while also generating high-margin recurring revenue from services and spare parts over the life of those tools. Over the past 52 weeks, AMAT stock has jumped 124% , with another 35% gain year-to-date (YTD). That strong run also shows up in valuation, with AMAT...
Yet passing a final vote was always likely to be a tall order, with several parliamentarians backing the bill at stage one not because they supported the law, but because they thought it was an issue that ought to be debated in-depth.
Yet passing a final vote was always likely to be a tall order, with several parliamentarians backing the bill at stage one not because they supported the law, but because they thought it was an issue that ought to be debated in-depth.
Memory chips maker Micron (NYSE:MU) will be announcing earnings results this Wednesday afternoon. Here’s what you need to know. Micron beat analysts’ revenue expectations last quarter, reporting revenues of $13.64 billion, up 56.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS and adjusted operating income estimates. Is Micron a buy or sell going into ea...
Memory chips maker Micron (NYSE:MU) will be announcing earnings results this Wednesday afternoon. Here’s what you need to know. Micron beat analysts’ revenue expectations last quarter, reporting revenues of $13.64 billion, up 56.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS and adjusted operating income estimates. Is Micron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Micron’s revenue to grow 147% year on year, improving from the 38.3% increase it recorded in the same quarter last year. Micron Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Micron rarely misses Wall Street’s revenue estimates. With Micron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for semiconductors stocks. However, the whole sector has faced a sell-off over the last month with stocks in Micron’s peer group down 6% on average. Micron is up 12% during the same time . ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Memory chips maker Micron (NYSE:MU) will be announcing earnings results this Wednesday afternoon. Here’s what you need to know. Micron beat analysts’ revenue expectations last quarter, reporting revenues of $13.64 billion, up 56.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS and adjusted operating income estimates. Is Micron a buy or sell going into ea...
Memory chips maker Micron (NYSE:MU) will be announcing earnings results this Wednesday afternoon. Here’s what you need to know. Micron beat analysts’ revenue expectations last quarter, reporting revenues of $13.64 billion, up 56.7% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS and adjusted operating income estimates. Is Micron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Micron’s revenue to grow 147% year on year, improving from the 38.3% increase it recorded in the same quarter last year. Micron Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Micron rarely misses Wall Street’s revenue estimates. With Micron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for semiconductors stocks. However, the whole sector has faced a sell-off over the last month with stocks in Micron’s peer group down 6% on average. Micron is up 12% during the same time . ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Pep Guardiola responds to a question about his failures in Europe with Manchester City after his side exited the Champions League following defeat to Real Madrid in the last 16. MATCH REPORT: Man City 1-2 Real Madrid (1-5 Agg) Available to UK users only.
Pep Guardiola responds to a question about his failures in Europe with Manchester City after his side exited the Champions League following defeat to Real Madrid in the last 16. MATCH REPORT: Man City 1-2 Real Madrid (1-5 Agg) Available to UK users only.
Earnings Call Insights: IZEA Worldwide, Inc. (IZEA) Q4 2025 Management View CEO Patrick Venetucci announced that the company delivered on its commitment to accelerate its path to profitability, highlighting "we broke even, increased cash, held managed services revenue relatively flat, excluding Hoozu, and grew our enterprise accounts faster than the market." Venetucci detailed a net profit swing o...
Earnings Call Insights: IZEA Worldwide, Inc. (IZEA) Q4 2025 Management View CEO Patrick Venetucci announced that the company delivered on its commitment to accelerate its path to profitability, highlighting "we broke even, increased cash, held managed services revenue relatively flat, excluding Hoozu, and grew our enterprise accounts faster than the market." Venetucci detailed a net profit swing of $18.9 million year-on-year and cited an annual revenue of $31.2 million, noting a "13% decrease that reflects a deliberate strategic pivot toward long-term profitability compounded by broader macroeconomic headwinds." Venetucci explained the company "successfully exited international markets and off-boarded lower-margin SMB accounts to prioritize a high potential enterprise portfolio," and described government-induced disruptions and trade policies negatively impacting government and retail accounts. He emphasized that "Managed services revenue, excluding Hoozu, remained resilient," and that enterprise accounts expanded above industry growth rates, with five accounts surpassing the $1 million threshold and delivering double or triple-digit growth. Venetucci highlighted a "40% reduction in total operating expenses" and a cash operating profit recovery to $0.7 million from a prior $11.1 million loss. The company is also preparing to launch a proprietary AI-infused technology platform for account management and is "extremely active in M&A discussions searching for companies that can build these capabilities faster and accelerate the growth of our enterprise client portfolio." CFO Peter Biere reported, "we reduced our annual cash operating costs in 2025 by over 40% and or $10 million, while increasing our investment in enterprise account management personnel where we're seeing growth." Biere added, "we're on track posting positive cash from operations and breakeven net income for the year, both of which show significant improvement over 2024 results." Outlook Management expec...
It has been a wild ride for Hims & Hers (HIMS +0.66%) shareholders over the last few years. The stock is currently in a 65% drawdown from its highs, but up 50% in March, due to the telehealth platform's latest deal with a weight-loss drugmaker that was formerly suing it. Now, Hims & Hers is teaming up with its former enemies. Here are two S&P 500 index stocks to watch after this latest Hims & Hers...
It has been a wild ride for Hims & Hers (HIMS +0.66%) shareholders over the last few years. The stock is currently in a 65% drawdown from its highs, but up 50% in March, due to the telehealth platform's latest deal with a weight-loss drugmaker that was formerly suing it. Now, Hims & Hers is teaming up with its former enemies. Here are two S&P 500 index stocks to watch after this latest Hims & Hers stock move, and what it means for the future of the weight-loss market. Watch the weight-loss drugmakers This deal with Hims & Hers shows the power that weight-loss drugmakers have in the market today. Initially led by Novo Nordisk (NVO 0.44%), the market is now dominated by Eli Lilly's (LLY 5.94%) Zepbound. This has helped Eli Lilly's business grow quickly in recent quarters, while Novo Nordisk's business has stagnated. However, both companies' revenues are up around 200% in the past 10 years. Eli Lilly has a partnership with Hims & Hers competitor Ro, while Novo Nordisk is now (maybe reluctantly) in a deal with Hims & Hers. Both drugmakers likely want it to be easier for customers to get these weight-loss drugs delivered directly to their doors, which will hopefully spur customer demand. Expand NYSE : HIMS Hims & Hers Health Today's Change ( 0.66 %) $ 0.17 Current Price $ 25.05 Key Data Points Market Cap $5.7B Day's Range $ 24.00 - $ 25.23 52wk Range $ 13.74 - $ 70.43 Volume 851K Avg Vol 32M Gross Margin 60.86 % These partnerships indicate that the industry's power lies with pharmaceutical giants such as Novo Nordisk and Eli Lilly. They have spent billions of dollars researching these drugs and getting them approved by regulators. Regardless of whether they are sold through Hims & Hers, Ro, or another telehealth platform, most of the profits flow back to the drugmakers. This is why both drugmakers earn over $15 billion in net income a year. Hims & Hers is barely profitable as a drug reseller. Weight-loss drugs are perhaps the fastest-growing pharmaceutical category in hi...
Key Points Hims & Hers' stock is up after ending its lawsuit with Novo Nordisk. The deal shows that industry power lies with the drugmakers. Both Novo Nordisk and Eli Lilly are key stocks to watch in this sector. 10 stocks we like better than Hims & Hers Health › It has been a wild ride for Hims & Hers (NYSE: HIMS) shareholders over the last few years. The stock is currently in a 65% drawdown from...
Key Points Hims & Hers' stock is up after ending its lawsuit with Novo Nordisk. The deal shows that industry power lies with the drugmakers. Both Novo Nordisk and Eli Lilly are key stocks to watch in this sector. 10 stocks we like better than Hims & Hers Health › It has been a wild ride for Hims & Hers (NYSE: HIMS) shareholders over the last few years. The stock is currently in a 65% drawdown from its highs, but up 50% in March, due to the telehealth platform's latest deal with a weight-loss drugmaker that was formerly suing it. Now, Hims & Hers is teaming up with its former enemies. Here are two S&P 500 index stocks to watch after this latest Hims & Hers stock move, and what it means for the future of the weight-loss market. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Watch the weight-loss drugmakers This deal with Hims & Hers shows the power that weight-loss drugmakers have in the market today. Initially led by Novo Nordisk (NYSE: NVO), the market is now dominated by Eli Lilly's (NYSE: LLY) Zepbound. This has helped Eli Lilly's business grow quickly in recent quarters, while Novo Nordisk's business has stagnated. However, both companies' revenues are up around 200% in the past 10 years. Eli Lilly has a partnership with Hims & Hers competitor Ro, while Novo Nordisk is now (maybe reluctantly) in a deal with Hims & Hers. Both drugmakers likely want it to be easier for customers to get these weight-loss drugs delivered directly to their doors, which will hopefully spur customer demand. These partnerships indicate that the industry's power lies with pharmaceutical giants such as Novo Nordisk and Eli Lilly. They have spent billions of dollars researching these drugs and getting them approved by regulators. Regardless of whether they are sold through Hims & Hers, Ro, or another telehealth platform,...
Kansas Introduces Medical Freedom Act; Would Impose $50,000 Fines For Vax Mandates Or Medical Discrimination Authored by Jon Fleetwood via JonFleetwood.com , A new bill introduced last week in the Kansas Legislature would prohibit government agencies, employers, schools, and businesses from denying services or employment based on a person’s medical decisions, including whether they accept or refus...
Kansas Introduces Medical Freedom Act; Would Impose $50,000 Fines For Vax Mandates Or Medical Discrimination Authored by Jon Fleetwood via JonFleetwood.com , A new bill introduced last week in the Kansas Legislature would prohibit government agencies, employers, schools, and businesses from denying services or employment based on a person’s medical decisions, including whether they accept or refuse vaccines, tests, masks, or other medical interventions. The legislation, Kansas Senate Bill 522 , was introduced March 2, 2026, during the 2025–2026 legislative session and is currently pending before the Senate Public Health and Welfare Committee, where lawmakers are scheduled to consider the measure in a committee hearing. The bill was requested for introduction by the Kansas Senate Committee on Federal and State Affairs , a legislative committee responsible for advancing policy proposals related to statewide governance and regulatory matters. You can contact Kansas state senators here and voice your support for the bill. What the Bill Would Do SB522 would establish the “Kansas Medical Freedom Act,” prohibiting both government and private entities from denying services, employment, access to events, or public benefits based on whether an individual accepts or refuses a medical intervention. The legislation defines “medical intervention” broadly to include vaccines, masks, diagnostic tests, medications, devices, and other health-related treatments. Under the proposal: Private businesses could not deny services or access to individuals based on their use or refusal of medical interventions. Employers—both public and private—could not require medical interventions as a condition of employment. Schools, conferences, and educational institutions could not require medical interventions for entry or participation. Government agencies could not condition licenses, permits, benefits, or access to public buildings or transportation on compliance with a medical intervention. The b...
Explore the exciting world of Corning (NYSE: GLW) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 17, 2026. Should you buy stock in Corning right now? Before you buy stock in...
Explore the exciting world of Corning (NYSE: GLW) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 17, 2026. Should you buy stock in Corning right now? Before you buy stock in Corning, consider this: Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Corning wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $513,407!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,123,237!* Now, it’s worth noting Stock Advisor’s total average return is 938% — a market-crushing outperformance compared to 188% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of March 17, 2026. Anand Chokkavelu has no position in any of the stocks mentioned. Lou Whiteman has no position in any of the stocks mentioned. Travis Hoium has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corning. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Key Points I'll look at five major producers’ latest dividend actions (raises, payout structure changes, and streak extensions) alongside the specific shareholder-return commitments they’re making. Free cash flow strength, record production, synergy plans, and buyback authorizations that run into the tens of billions make these stocks solid options in the current market environment. 10 stocks we l...
Key Points I'll look at five major producers’ latest dividend actions (raises, payout structure changes, and streak extensions) alongside the specific shareholder-return commitments they’re making. Free cash flow strength, record production, synergy plans, and buyback authorizations that run into the tens of billions make these stocks solid options in the current market environment. 10 stocks we like better than Devon Energy › When oil crossed $80 a barrel in early 2024, the largest U.S. energy producers faced a familiar choice: drill aggressively or return cash to shareholders. They chose the latter. Dividend raises, buyback programs, and capital return commitments accelerated as free cash flow swelled. Oil price volatility is reshaping how energy companies allocate capital, and the dividend story is the clearest expression of that shift. Here are the five energy stocks that doubled down hardest on shareholder returns. #5: Devon Energy Devon Energy (NYSE:DVN) ranks fifth on dividend commitment, but its forward story is the most dramatic of the group. The current quarterly dividend sits at $0.24 per share, leading to a 2.1% yield. Devon shifted to a fixed dividend structure in 2025, prioritizing predictability over volatility-linked payouts. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The real catalyst is its pending all-stock merger with Coterra Energy, expected to close in Q2 2026. Post-merger, the dividend is expected to increase 31% to $0.315 per quarter, and a new $5 billion-plus share repurchase authorization is planned. Devon's $0.24 ex-dividend date falls on March 13, 2026, with payment due March 31, 2026. Shares have gained 22% already, year to date. #4: EOG Resources EOG Resources (NYSE:EOG) has built a steady dividend growth record alongside production expansion. The current quarter...
Pep Guardiola is one of the greatest managers of all time. The Spaniard has won 12 domestic league titles during his tenures at Barcelona, Bayern Munich and then Manchester City, along with an abundance of domestic trophies and individual accolades. In the Champions League, his three titles - two with Barca and one with City - put him among the greats with only five-time winner Carlo Ancelotti hav...
Pep Guardiola is one of the greatest managers of all time. The Spaniard has won 12 domestic league titles during his tenures at Barcelona, Bayern Munich and then Manchester City, along with an abundance of domestic trophies and individual accolades. In the Champions League, his three titles - two with Barca and one with City - put him among the greats with only five-time winner Carlo Ancelotti having won more. But a 5-1 aggregate defeat by Real Madrid in the last 16 represents another missed opportunity and leaves many wondering what might have been. In the 15 years since lifting the Champions League trophy with Barcelona in 2011, his second with the Catalan club having also won it in 2009, Guardiola has only had his hands on the trophy once - a maiden title for City when they did the Treble in 2023. Guardiola himself would perhaps be disappointed with that yield, having come so close to adding to that tally on several occasions with City. "We have an extraordinary team and extraordinary group of players, the future is bright," said a defiant City boss after Tuesday's exit. But, given the uncertainty around his future in Manchester beyond this season, questions will be asked around whether this was the 55-year-old's last chance to win the coveted trophy.